Top

Published in:

01-03-2011 | Review

p53 Status and Its Prognostic Role in Extrahepatic Bile Duct Cancer: A Meta-Analysis of Published Studies

Authors: Juan Wang, Xuefeng Wang, Shuyang Xie, Zhonghai Yan, Zunling Li, Youjie Li, Lei Wang, Fei Jiao

Published in: Digestive Diseases and Sciences | Issue 3/2011

Abstract

The dysfunction of p53 is the most common genetic alteration in human cancer. A variety of studies have investigated the clinicopathologic correlation of p53 and its impact on patient survival in different types of cancer. For extrahepatic bile duct cancer (EBDC), however, the results were limited and conflicting. In this study, we performed an investigation to confirm whether there was a correlation between p53 status and some routine parameters. To further observe the impact of p53 on the survival of EBDC patients, a meta-analysis based on published studies was conducted. Candidate studies were searched from PubMed, EMBASE, and ISI Web of Science. Our results demonstrated that there were significant correlations between p53 expression and some clinicopathological parameters. Furthermore, the pooled results of the meta-analysis showed that the combined hazard ratio (HR) estimate for overall survival (OS) was 1.53 (95% CI, 1.10–2.14) and 1.23 (95% CI, 0.93–1.75) in univariate and multivariate analysis, respectively. In conclusion, the high level of p53 appears to be an effective prognostic factor to OS of EBDC patients. However, some limitations unavoidable in this meta-analysis and problems of previous p53 studies in EBDC mean that further studies are necessary before significant conclusions can be made.

Sandhu DS, Roberts LR. Diagnosis and management of cholangiocarcinoma. Curr Gastroenterol Rep. 2008;10:43–52.CrossRefPubMed

Briggs CD, Neal CP, Mann CD, et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer. 2009;45:33–47.CrossRefPubMed

Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873–875.CrossRefPubMed

Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–321.CrossRefPubMed

Bonney GK, Craven RA, Prasad R, et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 2008;9:149–158.CrossRefPubMed

Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489–499.CrossRefPubMed

Cong WM, Bakker A, Swalsky PA, et al. Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study. J Cancer Res Clin Oncol. 2001;127:187–192.CrossRefPubMed

Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci. 2000;910:121–137.CrossRefPubMed

Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol. 1998;16:3158–3168.PubMed

10.

Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18:705–719.CrossRefPubMed

11.

Havlik R, Sbisà E, Tullo A, et al. Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors. Hepatogastroenterology. 2000;47:927–931.PubMed

12.

Rijken AM, Offerhaus GJ, Polak MM, et al. p53 expression as a prognostic determinant in resected distal bile duct carcinoma. Eur J Surg Oncol. 1999;25:297–301.CrossRefPubMed

13.

Cheng Q, Luo X, Zhang B, et al. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann Surg Oncol. 2007;14:1212–1219.CrossRefPubMed

14.

Argani P, Shaukat A, Kaushal M, et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer. 2001;91:1332–1341.CrossRefPubMed

15.

Suto T, Sugai T, Nakamura S, et al. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer. 1998;82:86–95.CrossRefPubMed

16.

Lee YC, Song SY, Chung JB, et al. p53 protein expression in extrahepatic bile duct cancer. Yonsei Med J. 1996;37:112–117.PubMed

17.

Santini D, Tonini G, Vecchio FM, et al. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J Clin Pathol. 2005;58:159–165.CrossRefPubMed

18.

Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834.CrossRefPubMed

19.

Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92:434–444.PubMed

20.

Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer. 1999;80:1968–1973.CrossRefPubMed

21.

Huncharek M, Kupelnick B, Geschwind JF, et al. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett. 2000;153:219–226.CrossRefPubMed

22.

Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16–31.CrossRefPubMed

23.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.PubMed

24.

Suto T, Sugai T, Nakamura S, et al. Immunohistochemical detection of proliferating cell nuclear antigen and p53 expression in carcinoma of the extrahepatic bile duct. Oncology. 1997;54:407–413.CrossRefPubMed

25.

Hoang MP, Murakata LA, Katabi N, et al. Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol. 2002;15:1251–1258.CrossRefPubMed

26.

Albores-Saavedra J, Murakata L, Krueger JE, et al. Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts. Cancer. 2000;89:508–515.CrossRefPubMed

27.

Li X, Hui AM, Takayama T, et al. Altered p21WAF1/CIP1 expression is associated with poor prognosis in extrahepatic bile duct carcinoma. Cancer Lett. 2000;154:85–91.CrossRefPubMed

28.

Takashima M, Ueki T, Nagai E, et al. Carcinoma of the ampulla of Vater associated with or without adenoma: a clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions. Mod Pathol. 2000;13:1300–1307.CrossRefPubMed

29.

Park SH, Kim YI, Park YH, et al. Clinicopathologic correlation of p53 protein overexpression in adenoma and carcinoma of the ampulla of Vater. World J Surg. 2000;24:54–59.CrossRefPubMed

30.

Mann CD, Neal CP, Garcea G, et al. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979–992.CrossRefPubMed

31.

Levine AJ. The p53 tumor-suppressor gene. N Engl J Med. 1992;326:1350–1352.CrossRefPubMed

32.

Scott N, Sagar P, Stewart J, et al. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer. 1991;63:317–319.CrossRefPubMed

33.

Wong P, Verselis SJ, Garber JE, et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li–Fraumeni syndrome. Gastroenterology. 2006;130:73–79.CrossRefPubMed

34.

Soussi T, Béroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat. 2003;21:192–200.CrossRefPubMed

35.

Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene. 2007;26:2145–2156.CrossRefPubMed

36.

Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst. 2007;99:236–243.CrossRefPubMed

37.

Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005;97:1043–1055.CrossRefPubMed

38.

Jarnagin WR, Klimstra DS, Hezel M, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol. 2006;24:1152–1160.CrossRefPubMed

39.

Caca K, Feisthammel J, Klee K, et al. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer. 2002;97:481–488.CrossRefPubMed

40.

Khan SA, Thomas HC, Toledano MB, et al. p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 2005;25:704–716.CrossRefPubMed

41.

Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157–2165.CrossRefPubMed

42.

Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6:678–686.CrossRefPubMed

43.

Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004;4:793–805.CrossRefPubMed

44.

Della Torre G, Pasquini G, Pilotti S, et al. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas. Diagn Mol Pathol. 2000;9:41–46.CrossRefPubMed

45.

Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer. 2007;7:165–168.CrossRefPubMed

46.

Zaika AI, El-Rifai W. The role of p53 protein family in gastrointestinal malignancies. Cell Death Differ. 2006;13:935–940.CrossRefPubMed

47.

Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene. 2007;26:5169–5183.CrossRefPubMed

48.

Hong SM, Cho H, Moskaluk CA, et al. p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance. J Mol Histol. 2007;38:167–175.CrossRefPubMed

Title: p53 Status and Its Prognostic Role in Extrahepatic Bile Duct Cancer: A Meta-Analysis of Published Studies
Authors: Juan Wang
Xuefeng Wang
Shuyang Xie
Zhonghai Yan
Zunling Li
Youjie Li
Lei Wang
Fei Jiao
Publication date: 01-03-2011
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 3/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-010-1352-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in “Stem-Cell-Like” Tumor Cells

What Do Brazilian Pediatricians Know About Celiac Disease?

Corticosteroids Modulate Angiogenic Soluble Factors in Ulcerative Colitis Patients

Experience with the New 4-Way, 5.5-mm Ultrathin Endoscope: A Case Series

Ileoscopy via Stoma After Diverting Ileostomy: A Safe and Effective Tool to Evaluate for Crohn’s Recurrence of Neoterminal Ileum

U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials